International journal of urology : official journal of the Japanese Urological Association · 2025
Expression of Glucocorticoid Receptor Beta in Bladder Cancer and Its Clinicopathological Significance: A Novel Diagnostic Marker to Predict Progression and Recurrence of Cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kukimoto Takashi, Nakamura Yasuhiro, Hata Shuko, Shimada Hiroki, Ogata Tomoaki, Kato Masashi, Saito Haruka, Kusumoto Hiroki, Oikawa Masaaki, Morozumi Kento, Numakura Kazuyuki, Narita Shintaro, Sato Makoto, Habuchi Tomonori, Kaiho Yasuhiro
Аннотация
OBJECTIVES: The glucocorticoid receptor beta (GRβ) not only inhibits the function of the glucocorticoid receptor but also possesses unique transcriptional activity. Whereas the role of GRβ varies among different cancer types, its significance in bladder cancer remains unclear. This study aimed to investigate the clinical significance of GRβ expression in bladder cancer.
METHODS: Immunohistochemical analysis was performed on tissue samples obtained from 106 patients who underwent surgery for bladder cancer. The immunoreactivity of GRβ was evaluated using the labeling index (0%-100%). The association between GRβ expression and clinical parameters obtained from medical records was analyzed.
RESULTS: GRβ expression was significantly lower in muscle-invasive bladder cancer (≥ pT2) compared with non-muscle-invasive cases (≤ pT1) (p = 0.0177). Furthermore, patients who experienced intravesical recurrence after surgery exhibited significantly lower GRβ expression (p = 0.0179).
CONCLUSIONS: These findings suggest that GRβ may serve as a potential biomarker for predicting the progression and recurrence of bladder cancer.
METHODS: Immunohistochemical analysis was performed on tissue samples obtained from 106 patients who underwent surgery for bladder cancer. The immunoreactivity of GRβ was evaluated using the labeling index (0%-100%). The association between GRβ expression and clinical parameters obtained from medical records was analyzed.
RESULTS: GRβ expression was significantly lower in muscle-invasive bladder cancer (≥ pT2) compared with non-muscle-invasive cases (≤ pT1) (p = 0.0177). Furthermore, patients who experienced intravesical recurrence after surgery exhibited significantly lower GRβ expression (p = 0.0179).
CONCLUSIONS: These findings suggest that GRβ may serve as a potential biomarker for predicting the progression and recurrence of bladder cancer.